{"id":"W4405516329","doi":"10.21203/rs.3.rs-5632942/v1","title":"FRAME: A phase I trial of defactinib (FAK inhibitor) in combination with avutometinib (RAF-MEK clamp) in patients with solid tumours including low grade serous ovarian cancer","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Royal Ottawa Mental Health Centre; Institute of Cancer Research","funders":"Royal Marsden NHS Foundation Trust","keywords":"Medicine; Tolerability; Pharmacokinetics; MEK inhibitor; Pharmacodynamics; Ovarian cancer; Internal medicine; Clinical endpoint; Oncology; Serous fluid; Confidence interval; Dosing; Clinical trial; Cancer; MAPK/ERK pathway; Pharmacology; Adverse effect; Kinase; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006386543,0.001072372,0.0009815136,0.0002785773,0.0002517044,0.0008116095,0.0005282928,0.001093581,0.0124758],"category_scores_gemma":[0.0005582003,0.0003409408,0.001105812,0.0002218955,0.0004702077,0.0006398424,0.0003610722,0.002090062,0.002152905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005467797,"about_ca_system_score_gemma":0.0008535262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009965223,"about_ca_topic_score_gemma":0.003236315,"domain_scores_codex":[0.9998716,0.00004303302,0.000003944101,0.00002521098,0.00001222814,0.00004391388],"domain_scores_gemma":[0.999828,0.00002707041,0.00002552598,0.00001382616,0.000009467935,0.00009617534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6375858,0.01783453,0.002872074,0.001318774,0.001761359,0.0004816014,0.0001978071,0.003485274,0.03992159,0.001133044,0.04370419,0.249704],"study_design_scores_gemma":[0.7928475,0.167485,0.009888119,0.0001247086,0.0008480573,0.0005371864,0.00009459702,0.001608061,0.004686686,0.000935253,0.02088826,0.00005655783],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9626694,0.007881694,0.001683707,0.004362727,0.001021663,0.002134206,0.007079555,0.0006094372,0.01255756],"genre_scores_gemma":[0.9560151,0.005481494,0.003494295,0.003323456,0.00057783,0.002238937,0.009912052,0.0001575332,0.01879938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0124758,"threshold_uncertainty_score":0.04173577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04171688311191956,"score_gpt":0.3854444483205771,"score_spread":0.3437275652086575,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}